Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir

• Published in: International journal of infectious diseases Vol. 46; pp. 82 - 88
• Main Authors: Borzacov, Lourdes Maria Pinheiro, de Figueiredo Nicolete, Larissa Deadame, Souza, Luan Felipo Botelho, dos Santos, Alcione Oliveira, Vieira, Deusilene Souza, Salcedo, Juan Miguel Villalobos
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.05.2016
• Subjects: Adult; Aged; Antiviral Agents - administration & dosage; Drug Therapy, Combination; Entecavir; Female; Genotype; Genotype 3; Guanine - administration & dosage; Guanine - analogs & derivatives; HDV; Hepatitis D - drug therapy; Hepatitis D - virology; Hepatitis Delta Virus - drug effects; Hepatitis Delta Virus - genetics; Hepatitis Delta Virus - physiology; Humans; Infectious Disease; Interferon-alpha - administration & dosage; Male; Middle Aged; PEG-IFN; Polyethylene Glycols - administration & dosage; Prospective Studies; Pulmonary/Respiratory; Recombinant Proteins - administration & dosage; RNA, Viral - genetics; Treatment; Young Adult; PEG-IFN; Treatment; HDV; Genotype 3; Entecavir; .

•The effects of therapy with pegylated interferon alpha 2a (PEG-IFN) were evaluated in patients with hepatitis delta virus genotype 3 (HDV-3) and these were correlated with a possible cure rate higher than expected.•The therapeutic protocol used in this study presented a satisfactory response level...